🚀
Enjoy a 7-Day Free Trial Thru May 02, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
AnaptysBio Inc (NAS:ANAB)
News
AnaptysBio Inc
2
1
NAS
:ANAB (USA) Â
$ 18.69
-0.58 (-3.01%)
10:00 AM EST
P/E:
At Loss
P/B:
5.65
Market Cap:
$ 500.20M
Enterprise V:
$ 144.51M
Volume:
29.63K
Avg Vol (2M):
358.28K
Warning! GuruFocus detected 5 Severe warning signs with ANAB.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
29.63K
Market Cap $:
500.20M
PE Ratio:
At Loss
Avg Vol (2M):
358.28K
Enterprise Value $:
144.51M
PB Ratio:
5.65
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
AnaptysBio Inc (NAS:ANAB) Stock News, Headlines & Updates
AnaptysBio Inc Stock News from GuruFocus
Total 166
1
2
3
4
5
Apr 24, 2024
Actym Therapeutics Appoints Thomas Smart as CEO
PRNewswire
•
9:00am
Feb 15, 2024
Steven Cohen's Point72 Asset Management Reduces Stake in AnaptysBio Inc
GuruFocus Research
•
2:13am
Feb 06, 2024
AnaptysBio Inc to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event Transcript
GuruFocus Research
•
7:55pm
AnaptysBio Inc To virtual BTLA Agonist (ANB032) R&D Event Transcript
GuruFocus Research
•
7:55pm
AnaptysBio Inc at JPMorgan Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
7:55pm
AnaptysBio Inc at JPMorgan Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
7:55pm
AnaptysBio Inc at Jefferies Virtual London Healthcare Conference Transcript
GuruFocus Research
•
7:55pm
AnaptysBio Inc at JPMorgan Healthcare Conference Transcript
GuruFocus Research
•
7:55pm
AnaptysBio Inc at Bank of America Merrill Lynch Health Care Conference Transcript
GuruFocus Research
•
7:55pm
Jan 12, 2024
AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares
GuruFocus Research
•
2:02pm
Nov 27, 2023
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
GlobeNewswire
•
5:00pm
Nov 04, 2023
AnaptysBio Inc (ANAB) Reports Q3 2023 Financial Results and Business Updates
GuruFocus Research
•
3:41am
Nov 01, 2023
Anaptys Announces Participation in November Investor Conferences
Marketwired
•
9:00am
Oct 11, 2023
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
Marketwired
•
9:00am
Oct 09, 2023
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Marketwired
•
8:00am
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Marketwired
•
7:00am
Sep 19, 2023
Insider Sell: Eric Loumeau Sells 6,000 Shares of AnaptysBio Inc
GuruFocus Research
•
1:01pm
Sep 18, 2023
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
Marketwired
•
4:00pm
Sep 12, 2023
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
Marketwired
•
9:00am
Aug 07, 2023
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
Marketwired
•
4:00pm
Jul 31, 2023
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
Marketwired
•
1:00pm
Feb 27, 2023
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
sperokesalga
•
4:01pm
Jan 13, 2023
AnaptysBio Announces Stock Repurchase Plan
Stock market mentor
•
8:00am
Jan 05, 2023
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
Stock market mentor
•
4:00pm
Dec 02, 2022
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
Value_Insider
•
8:00am
Nov 21, 2022
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
Value_Insider
•
1:00pm
Nov 09, 2022
AnaptysBio to Participate in Upcoming November Investor Conferences
Value_Insider
•
2:00pm
Aug 31, 2022
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
Ds***
•
4:00pm
Aug 05, 2022
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
PurpleRose
•
3:00pm
Jul 02, 2022
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
GuruFocusNews
•
3:23pm
Jun 22, 2022
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
GuruFocusNews
•
3:20pm
Jun 12, 2022
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
GuruFocusNews
•
3:18pm
Jun 02, 2022
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
GuruFocusNews
•
3:17pm
May 14, 2022
Top 5 1st Quarter Trades of FEDERATED HERMES, INC.
GuruFocus Research
•
11:00pm
May 04, 2022
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
GuruFocusNews
•
4:01pm
Apr 27, 2022
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
GuruFocusNews
•
4:01pm
Mar 21, 2022
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
GuruFocusNews
•
4:00pm
Mar 14, 2022
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
GuruFocusNews
•
4:00pm
Jan 06, 2022
Recludix Pharma Announces Scientific Advisory Board
GuruFocusNews
•
8:01am
Jan 05, 2022
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
GuruFocusNews
•
4:00pm
Total 166
1
2
3
4
5
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news